Breast density is a major cause of the failure to detect breast cancer with screening mammography in pre-menopausal women. Tamoxifen is used for breast cancer risk reduction and treatment, but little is known about its effect on breast density, or the correlation between tamoxifen-induced changes in sex steroids and symptoms which decrease quality of life and limit the use of tamoxifen. The ideal agent would be one which decreased breast density without producing systemic effects. We propose to address this problem using full-field digital mammography to measure breast density reproducibility.
The specific aims are: 1) to correlate changes in breast density with the hormonal changes throughout the menstrual cycle using a salivary assay for sex steroids. This study will determine whether this is a significant factor which must be controlled for in intervention studies; 2) To evaluate the alterations in breast density produced by tamoxifen, and correlate changes in steroid hormone levels with changes in quality of life; and 3) to examine the use of a topically applied anti- estrogen, 4-hydroxytamoxifen, on breast density. The incidence of symptoms and changes in hormone levels will be assessed to determine the extent of systemic absorption and its clinical significance.. This study will provide useful information to women about the scheduling of mammographic examinations; determine if tamoxifen reduces breast density, another potential benefit of the drug for high-risk women; and ascertain whether a local strategy of density reduction is effective without producing systemic symptoms. If so, this would offer a major opportunity to improve our ability to detect breast cancer in the female population as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA089018-01
Application #
6402277
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Jordan, V Craig (2015) The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 22:R1-31
Arora, Hans C; Jensen, Mark P; Yuan, Ye et al. (2012) Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 72:769-78
Wu, Aiguo; Paunesku, Tatjana; Zhang, Zhuoli et al. (2011) A Multimodal Nanocomposite for Biomedical Imaging. AIP Conf Proc 1365:379
Thurn, Kenneth T; Arora, Hans; Paunesku, Tatjana et al. (2011) Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. Nanomedicine 7:123-30
Morrow, Monica; Chatterton Jr, Robert T; Rademaker, Alfred W et al. (2010) A prospective study of variability in mammographic density during the menstrual cycle. Breast Cancer Res Treat 121:565-74
Chatterton Jr, Robert Treat; Parker, Noah P; Habe-Evans, Mito et al. (2010) Breast ductal lavage for assessment of breast cancer biomarkers. Horm Cancer 1:197-204
Patel, Roshani R; Sengupta, Surojeet; Kim, Helen R et al. (2010) Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 46:1537-53
Balaburski, Gregor M; Dardes, Rita C; Johnson, Michael et al. (2010) Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol 37:387-98
Lewis-Wambi, Joan S; Jordan, V Craig (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11:206
Khan, Seema A; Lankes, Heather A; Patil, Deepa B et al. (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res (Phila) 2:265-73

Showing the most recent 10 out of 163 publications